Datasets Comparison

Both abrocitinib and dupilumab effectively improve skin barrier function in atopic dermatitis, with distinct molecular impacts unveiled through tape-strip proteomics analysis. This dataset contains supplemental methods, 6 supplemental figures, and 5 supplemental tables. Mendeley supplemental figure 1. Flow diagram of subject assignments and intervention adherence Mendeley supplemental figure 2. Representative clinical images of AD patients before and after treatment Mendeley supplemental figure 3. Comparison of laboratory test results before and after treatment with dupilumab or abrocitinib Mendeley supplemental figure 4. Correlation between clinical symptoms and skin barrier function during treatment Mendeley supplemental figure 5. Distinct Gene Ontology terms and potential biomarkers in AD skin Mendeley supplemental figure 6. Different therapies induce unique dynamic patterns of skin proteomics in AD Mendeley supplemental table 1. Baseline details of demographics and skin barrier parameters in enrolled individuals Mendeley supplemental table 2. Comparison of demographics and baseline clinical features within subgroups Mendeley supplemental table 3. Differentially expressed proteins between AD lesional skin at baseline and healthy skin Mendeley supplemental table 4. Differentially expressed proteins between AD non-lesional skin at baseline and healthy skin Mendeley supplemental table 5. Differentially expressed proteins between lesional skin and non-lesional skin of AD at baseline

Sun Yat-sen University First Affiliated Hospital

Proteomics, Atopic Dermatitis, Barrier Function of Stratum Corneum, Hydration

Creative Commons Attribution 4.0 International

Both abrocitinib and dupilumab effectively improve skin barrier function in atopic dermatitis, with distinct molecular impacts unveiled through tape-strip proteomics analysis. This dataset contains supplemental methods, 6 supplemental figures, and 5 supplemental tables. Mendeley supplemental figure 1. Flow diagram of subject assignments and intervention adherence Mendeley supplemental figure 2. Representative clinical images of AD patients before and after treatment Mendeley supplemental figure 3. Comparison of laboratory test results before and after treatment with dupilumab or abrocitinib Mendeley supplemental figure 4. Correlation between clinical symptoms and skin barrier function during treatment Mendeley supplemental figure 5. Distinct Gene Ontology terms and potential biomarkers in AD skin Mendeley supplemental figure 6. Different therapies induce unique dynamic patterns of skin proteomics in AD Mendeley supplemental table 1. Baseline details of demographics and skin barrier parameters in enrolled individuals Mendeley supplemental table 2. Comparison of demographics and baseline clinical features within subgroups Mendeley supplemental table 3. Differentially expressed proteins between AD lesional skin at baseline and healthy skin Mendeley supplemental table 4. Differentially expressed proteins between AD non-lesional skin at baseline and healthy skin Mendeley supplemental table 5. Differentially expressed proteins between lesional skin and non-lesional skin of AD at baseline

Sun Yat-sen University First Affiliated Hospital

Proteomics, Atopic Dermatitis, Barrier Function of Stratum Corneum, Hydration

Creative Commons Attribution 4.0 International